List of pharmaceutical compound number prefixes

Last updated

This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic chemical names, and for which the effort to generate nonproprietary names may not be warranted, see article on drug nomenclature. Instead, these compounds are usually given a number for internal reference at the company. To distinguish the numbered compounds from different companies (or academic laboratories), each compound number is prefixed with a letter code indicating the company that developed the compound, that claims intellectual property on that compound etc. The letter code is conceived by companies themselves who should be interested in creating a unique code. Three main methods are found for prefixing the numeric identifier – with a space (gap), [1] with nothing (concatenated), [2] [3] and with a dash (or hyphen). [4]

Contents

For example, ABT-199 is a compound developed at Abbott Laboratories, and this name has been used in early publications of research results. Later the compound was assigned the international nonproprietary name (INN) venetoclax. Similarly, other compounds may be given a USAN or BAN for example. Finally, the compound may be given a trade name for example for marketing purposes.

A long list of code designations with corresponding trade names can be found in Appendix IV of the USP Dictionary, see article on drug nomenclature.

Note that this convention of composing compound identifiers from a company identifier followed by a number is not always followed. For example, the letter code may reflect a therapeutic/disease area or an internal project name. A randomly picked example is SC for spinal cord injury. [5]

A to F

G to L

M to S

T to Z

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849, in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

<span class="mw-page-title-main">Novartis</span> Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

<span class="mw-page-title-main">Pharmaceutical Research and Manufacturers of America</span> Trade group

Pharmaceutical Research and Manufacturers of America, formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. PhRMA is headquartered in Washington, D.C.

Astex Pharmaceuticals is a biotechnology company focused on the discovery and development of drugs in oncology and diseases of the central nervous system. Astex was founded in 1999 by Sir Tom Blundell, Chris Abell & Harren Jhoti, and is located in Cambridge, England.

<span class="mw-page-title-main">Fred Hassan</span> American businessman

Fred Hassan, is a Pakistan-born American business executive who works for the private equity giant Warburg Pincus and previously was CEO of three global pharmaceutical companies.

IMA Life S.r.l is one of the few companies which are prominent in the manufacturing of freeze dryers especially for the pharmaceutical and biotechnological companies, aseptic processing and filling solutions. It was previously owned by the BOC Group and then the Linde Group until recently when it was bought by the IMA Group based in Italy.

Sir Menelaos (Mene) Nicolas Pangalos is a British neuroscientist of Greek descent.

The National Health Council (NHC) is a nonprofit association of health organizations.

SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and shut down in 2003, after developing the pioneering kinase inhibitor drug sunitinib (Sutent).

<span class="mw-page-title-main">National Organization for Rare Disorders</span> U.S. nonprofit organization

The National Organization for Rare Disorders (NORD) is a nonprofit organization, based in Connecticut, aiming to provide support for individuals with rare diseases by advocating and funding research, education, and networking among service providers. It was founded in 1983 by Abbey Meyers, along with individuals and rare diseases leaders of rare disease support groups, and it is a 501(c)(3) tax exempt organization.

<span class="mw-page-title-main">Cambridge Antibody Technology</span> Defunct British biotechnology company

Cambridge Antibody Technology Group Plc, was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology.

The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.

The pharmaceutical industry in Puerto Rico encompasses more than half of all manufacturing done in Puerto Rico. As the island's most prominent industry, pharmaceutics generates more than 18,000 jobs, pays more than US$3 billion in taxes, comprises about half of total exports, and has generated more than 25% of the island's GDP for the past four decades. Comparatively, Puerto Rico is the fifth largest area in the world for pharmaceutical manufacturing with more than 80 plants, including:

The Verband Forschender Arzneimittelhersteller (vfa) or Association of Research-Based Pharmaceutical Companies, is the trade group of 43 pharmaceutical companies in Germany which are global players, representing more than two-thirds of the German pharmaceutical market, with nearly 80,000 employees in Germany.

<span class="mw-page-title-main">Innovative Medicines Canada</span> Association of pharmaceutical companies

Innovative Medicines Canada (IMC) is a national association of pharmaceutical companies that represents the interests of the research-based pharmaceutical industry in Canada. Its membership includes biopharmaceutical companies, vaccine developers, and manufacturers of medical devices, and works with government agencies, insurance companies, healthcare professionals and other stakeholders in the regulation and promotion of medicines.

<span class="mw-page-title-main">Pharmaceutical Advertising Advisory Board</span> Canadian not-for-profit organization

The Pharmaceutical Advertising Advisory Board (PAAB) is a Canadian not-for-profit organization based in Pickering, Ontario. Acting as a pseudo-regulatory body, PAAB offers review and pre-clearance services recognized by Health Canada to pharmaceutical companies and marketing agencies who wish to advertise directly to consumers and/or healthcare professionals. It is financed on a fee-for-service basis.

BIOTECanada, previously the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ontario. It is an industry-funded membership organization composed of over 250 national and international pharmaceutical and gene therapy companies, medical device manufacturers, agricultural science businesses, law firms, academic institutions, research and development networks, advertising agencies, insurance companies and financial services firms.

References

  1. "ArQule clinical pipeline" . Retrieved 2016-09-16.
  2. 1 2 "Regeneron PCSK9 Antibody REGN727". Archived from the original on 2012-04-16. Retrieved 2012-04-17.
  3. 1 2 "Exelixis HSP90 inhibitor XL888". Archived from the original on 2016-09-18. Retrieved 2016-09-16.
  4. 1 2 "AbbVie pipeline, using ABBV- as prefix" . Retrieved 2016-09-16.
  5. "SC0806 clinical trial" . Retrieved 2018-07-26.
  6. 1 2 "AbbVie spun out of Abbott". Chicago Tribune . 30 December 2012. Retrieved 2016-09-15.
  7. "ADL5747" . Retrieved 2008-03-19.[ dead link ]
  8. "Amgen goes 6-for-6 in Phase III". 17 March 2014. Retrieved 2014-11-25.
  9. "Overview of R&D Pipeline" (PDF). Retrieved 2018-12-30.
  10. "Our Portfolio". Arecor Therapeutics. Retrieved 12 June 2023.
  11. Drawbaugh, Tom Bergin (16 November 2015). "How Pfizer has shifted U.S. profits overseas for years". Reuters. Retrieved 2019-11-06.
  12. "Edison outlook report on YM Biosciences" (PDF). Retrieved 2016-09-19.
  13. "Eagle Pharmacy – Pharmaceutical Compounding" . Retrieved 2016-04-26.
  14. 1 2 "Genentech Pipeline" . Retrieved 2016-09-29.
  15. Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; De Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Côté, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; et al. (2016). "GDC-0152". Journal of Medicinal Chemistry. 59 (23): 10549–10563. doi:10.1021/acs.jmedchem.6b01022. PMID   27682507.
  16. Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; De Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Côté, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; et al. (2016). "GNE-272". Journal of Medicinal Chemistry. 59 (23): 10549–10563. doi:10.1021/acs.jmedchem.6b01022. PMID   27682507.
  17. "First patients dosed in phase II study of GS-248 in systemic sclerosis". Bioworld Science. Clarivate Analytics. Retrieved 27 January 2021.
  18. "MBX 2109" . Retrieved 2024-02-12.
  19. "Pipeline – AstraZeneca" . Retrieved 2018-12-30.
  20. "Monte Rosa MRT-6160" . Retrieved 2024-11-25.
  21. "Neurocrine Vmat2 inhibitor NBI-98854". Archived from the original on 2015-01-30. Retrieved 2016-09-13.
  22. "Sunesis BTK inhibitor SNS-062" . Retrieved 2016-09-15.
  23. "Sensei biotherapeutics anti VISTA" (Press release). October 2021. Retrieved 2021-11-29.
  24. "Theravance Biopharma Pipeline". Theravance pipeline background image. Retrieved 2024-02-12.
  25. "Pipeline". Terns Pharma pipeline. Retrieved 27 January 2021.
  26. "TH-302 clinical trial" . Retrieved 2013-07-23.
  27. "MM&M News". 2008-12-18. Retrieved 2009-02-16.
  28. "TransMolecular Product Pipeline". Archived from the original on 2007-07-29. Retrieved 2007-11-18.
  29. "Pipeline". Totus Medicines Pipeline. Retrieved 25 August 2023.
  30. "TOS-358 Clinical Trial" . Retrieved 25 August 2023.
  31. "Preclinical characterization of TOS-358, a potent and selective covalent inhibitor of wild-type and mutant PI3Kα with superior anticancer activity" . Retrieved 25 August 2023.
  32. "Taisho Press Release" . Retrieved 2008-01-07.
  33. "UCL1684 at pubchem.gov" . Retrieved 2018-03-24.